J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Venkatakrishnan, K
Right arrow Articles by Greenblatt, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Venkatakrishnan, K
Right arrow Articles by Greenblatt, D.

Articles

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models

K Venkatakrishnan, LL Von Moltke, and DJ Greenblatt

The cytochromes P450 (CYPs) constitute a superfamily of hemoprotein enzymes that are responsible for the biotransformation of numerous xenobiotics, including therapeutic agents. Studies of the biochemical and enzymatic properties of these enzymes and their molecular genetics and regulation of gene expression and activity have greatly enhanced our understanding of several aspects of clinical pharmacology such as pharmacokinetic variability, drug toxicity, and drug interactions. This review evaluates the major human hepatic drug-metabolizing CYP enzymes and their clinically relevant substrates, inhibitors, and inducers. Also discussed are the molecular bases and clinical implications of genetic polymorphisms that affect the CYPs. Much of the information on the specificity of substrates and inhibitors of the CYP enzymes is derived from in vitro studies using human liver microsomes and heterologously expressed CYP enzymes. These methods are discussed, and guidelines are provided for designing enzyme kinetic and reaction phenotyping studies using multiple approaches. The strengths, weaknesses, and discrepancies among the different approaches are considered using representative examples. The mathematical models used in predicting the pharmacokinetic clearance of a drug from in vitro estimates of intrinsic clearance and the principles of quantitative in vitro-in vivo scaling of metabolic drug interactions are also discussed.


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
M. Kotsuma, T. Tokui, T. Ishizuka-Ozeki, T. Honda, H. Iwabuchi, T. Murai, T. Ikeda, and H. Saji
CYP2D6-Mediated Metabolism of a Novel Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitor, Pactimibe, and Its Unique Plasma Metabolite, R-125528
Drug Metab. Dispos., March 1, 2008; 36(3): 529 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
O. F. Iwuchukwu and S. Nagar
Resveratrol (trans-Resveratrol, 3,5,4'-Trihydroxy-trans-stilbene) Glucuronidation Exhibits Atypical Enzyme Kinetics in Various Protein Sources
Drug Metab. Dispos., February 1, 2008; 36(2): 322 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. C. L. Erve, S. C. Vashishtha, W. DeMaio, and R. E. Talaat
Metabolism of Prazosin in Rat, Dog, and Human Liver Microsomes and Cryopreserved Rat and Human Hepatocytes and Characterization of Metabolites by Liquid Chromatography/Tandem Mass Spectrometry
Drug Metab. Dispos., June 1, 2007; 35(6): 908 - 916.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Nagata, M. Hidaka, H. Sekiya, Y. Kawano, K. Yamasaki, M. Okumura, and K. Arimori
Effects of Pomegranate Juice on Human Cytochrome P450 2C9 and Tolbutamide Pharmacokinetics in Rats
Drug Metab. Dispos., February 1, 2007; 35(2): 302 - 305.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Zhang, L. Wang, G. Chandrasena, L. Ma, M. Zhu, H. Zhang, C. D. Davis, and W. G. Humphreys
Involvement of Multiple Cytochrome P450 and UDP-Glucuronosyltransferase Enzymes in the in Vitro Metabolism of Muraglitazar
Drug Metab. Dispos., January 1, 2007; 35(1): 139 - 149.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
H. Zhou
Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?
J. Clin. Pharmacol., November 1, 2006; 46(11): 1268 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
O. Bernard, J. Tojcic, K. Journault, L. Perusse, and C. Guillemette
Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid
Drug Metab. Dispos., September 1, 2006; 34(9): 1539 - 1545.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
V. Uchaipichat, P. I. Mackenzie, D. J. Elliot, and J. O. Miners
SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) "PROBES" FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES
Drug Metab. Dispos., March 1, 2006; 34(3): 449 - 456.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
D. J. Greenblatt, R. A. Leigh-Pemberton, and L. L. von Moltke
In Vitro Interactions of Water-Soluble Garlic Components with Human Cytochromes P450
J. Nutr., March 1, 2006; 136(3): 806S - 809S.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. J. Greenblatt, L. L. von Moltke, Y. Luo, E. S. Perloff, K. A. Horan, A. Bruce, R. C. Reynolds, J. S. Harmatz, B. Avula, I. A. Khan, et al.
Ginkgo biloba Does Not Alter Clearance of Flurbiprofen, a Cytochrome P450-2C9 Substrate
J. Clin. Pharmacol., February 1, 2006; 46(2): 214 - 221.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Thibaudeau, J. Lepine, J. Tojcic, Y. Duguay, G. Pelletier, M. Plante, J. Brisson, B. Tetu, S. Jacob, L. Perusse, et al.
Characterization of Common UGT1A8, UGT1A9, and UGT2B7 Variants with Different Capacities to Inactivate Mutagenic 4-Hydroxylated Metabolites of Estradiol and Estrone
Cancer Res., January 1, 2006; 66(1): 125 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Zhang, T. J. Chando, D. W. Everett, C. J. Patten, S. S. Dehal, and W. G. Humphreys
IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATION
Drug Metab. Dispos., November 1, 2005; 33(11): 1729 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. L. C. M. Dorne and A. G. Renwick
The Refinement of Uncertainty/Safety Factors in Risk Assessment by the Incorporation of Data on Toxicokinetic Variability in Humans
Toxicol. Sci., July 1, 2005; 86(1): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. Liu, R. F. Frye, R. A. Branch, R. Venkataramanan, J. J. Fung, and G. J. Burckart
Effect of Age and Postoperative Time on Cytochrome P450 Enzyme Activity Following Liver Transplantation
J. Clin. Pharmacol., June 1, 2005; 45(6): 666 - 673.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
G. A. Winchell, G. C. Mistry, P. P. Kari, T. Marbury, J. L. Miller, R. C. Simpson, A. D. Rodrigues, K. M. Gottesdiener, and J. A. Wagner
The Effect of Ketoconazole on the Pharmacokinetics of a Selective {alpha}1A-Adrenoceptor Antagonist
J. Clin. Pharmacol., June 1, 2005; 45(6): 699 - 703.
[Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Hidaka, M. Okumura, K.-i. Fujita, T. Ogikubo, K. Yamasaki, T. Iwakiri, N. Setoguchi, and K. Arimori
EFFECTS OF POMEGRANATE JUICE ON HUMAN CYTOCHROME P450 3A (CYP3A) AND CARBAMAZEPINE PHARMACOKINETICS IN RATS
Drug Metab. Dispos., May 1, 2005; 33(5): 644 - 648.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
O. V. Trubetskoy, J. R. Gibson, and B. D. Marks
Highly Miniaturized Formats for In Vitro Drug Metabolism Assays Using Vivid(R) Fluorescent Substrates and Recombinant Human Cytochrome P450 Enzymes
J Biomol Screen, February 1, 2005; 10(1): 56 - 66.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X. Song, Y. Li, J. Liu, M. Mukundan, and B. Yan
Simultaneous Substitution of Phenylalanine-305 and Aspartate-318 of Rat Pregnane X Receptor with the Corresponding Human Residues Abolishes the Ability to Transactivate the CYP3A23 Promoter
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 571 - 582.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
D. M. Dambach, B. A. Andrews, and F. Moulin
New Technologies and Screening Strategies for Hepatotoxicity: Use of In Vitro Models
Toxicol Pathol, January 1, 2005; 33(1): 17 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Picard and P. Marquet
IN VITRO STUDY OF MYCOPHENOLIC ACID GLUCURONIDATION
Drug Metab. Dispos., December 1, 2004; 32(12): 1524 - 1524.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Lepine, O. Bernard, M. Plante, B. Tetu, G. Pelletier, F. Labrie, A. Belanger, and C. Guillemette
Specificity and Regioselectivity of the Conjugation of Estradiol, Estrone, and Their Catecholestrogen and Methoxyestrogen Metabolites by Human Uridine Diphospho-glucuronosyltransferases Expressed in Endometrium
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5222 - 5232.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Ramirez, F. Innocenti, E. G. Schuetz, D. A. Flockhart, M. V. Relling, R. Santucci, and M. J. Ratain
CYP2B6, CYP3A4, AND CYP2C19 ARE RESPONSIBLE FOR THE IN VITRO N-DEMETHYLATION OF MEPERIDINE IN HUMAN LIVER MICROSOMES
Drug Metab. Dispos., September 1, 2004; 32(9): 930 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. B. Andersson, E. Bredberg, H. Ericsson, and H. Sjoberg
AN EVALUATION OF THE IN VITRO METABOLISM DATA FOR PREDICTING THE CLEARANCE AND DRUG-DRUG INTERACTION POTENTIAL OF CYP2C9 SUBSTRATES
Drug Metab. Dispos., July 1, 2004; 32(7): 715 - 721.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. M. Jones, D. Hallifax, and J. B. Houston
QUANTITATIVE PREDICTION OF THE IN VIVO INHIBITION OF DIAZEPAM METABOLISM BY OMEPRAZOLE USING RAT LIVER MICROSOMES AND HEPATOCYTES
Drug Metab. Dispos., May 1, 2004; 32(5): 572 - 580.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. S. Warrington, L. L. Von Moltke, J. S. Harmatz, R. I. Shader, and D. J. Greenblatt
THE EFFECT OF AGE ON SILDENAFIL BIOTRANSFORMATION IN RAT AND MOUSE LIVER MICROSOMES
Drug Metab. Dispos., November 1, 2003; 31(11): 1306 - 1309.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. H. Court, S. Krishnaswamy, Q. Hao, S. X. Duan, C. J. Patten, L. L. von Moltke, and D. J. Greenblatt
EVALUATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, MORPHINE, AND CODEINE AS PROBE SUBSTRATES FOR UDP-GLUCURONOSYLTRANSFERASE 2B7 (UGT2B7) IN HUMAN LIVER MICROSOMES: SPECIFICITY AND INFLUENCE OF THE UGT2B7*2 POLYMORPHISM
Drug Metab. Dispos., September 1, 2003; 31(9): 1125 - 1133.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. C. Patki, L. L. von Moltke, and D. J. Greenblatt
IN VITRO METABOLISM OF MIDAZOLAM, TRIAZOLAM, NIFEDIPINE, AND TESTOSTERONE BY HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROMES P450: ROLE OF CYP3A4 AND CYP3A5
Drug Metab. Dispos., July 1, 2003; 31(7): 938 - 944.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. P. Granvil, A.-M. Yu, G. Elizondo, T. E. Akiyama, C. Cheung, L. Feigenbaum, K. W. Krausz, and F. J. Gonzalez
Expression of the Human CYP3A4 Gene in the Small Intestine of Transgenic Mice: In Vitro Metabolism and Pharmacokinetics of Midazolam
Drug Metab. Dispos., May 1, 2003; 31(5): 548 - 558.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. M. Margolis and R. S. Obach
Impact of Nonspecific Binding to Microsomes and Phospholipid on the Inhibition of Cytochrome P4502D6: Implications for Relating in Vitro Inhibition Data to in Vivo Drug Interactions
Drug Metab. Dispos., May 1, 2003; 31(5): 606 - 611.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, S. M. Fogelman, G. Chen, J. A. Graf, P. Mertzanis, S. Byron, K. E. Culm, B. W. Granda, et al.
Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone
J. Clin. Pharmacol., April 1, 2003; 43(4): 414 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. S. Kalgutkar, T. J. Taylor, K. Venkatakrishnan, and E. M. Isin
Assessment of the Contributions of CYP3A4 and CYP3A5 in the Metabolism of the Antipsychotic Agent Haloperidol to Its Potentially Neurotoxic Pyridinium Metabolite and Effect of Antidepressants on the Bioactivation Pathway
Drug Metab. Dispos., March 1, 2003; 31(3): 243 - 249.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. M. Bertelsen, K. Venkatakrishnan, L. L. von Moltke, R. S. Obach, and D. J. Greenblatt
Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and Quinidine
Drug Metab. Dispos., March 1, 2003; 31(3): 289 - 293.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
T. Kislinger, K. Rahman, D. Radulovic, B. Cox, J. Rossant, and A. Emili
PRISM, a Generic Large Scale Proteomic Investigation Strategy for Mammals
Mol. Cell. Proteomics, February 1, 2003; 2(2): 96 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Krishnaswamy, S. X. Duan, L. L. von Moltke, D. J. Greenblatt, and M. H. Court
Validation of Serotonin (5-Hydroxtryptamine) as an in Vitro Substrate Probe for Human UDP-Glucuronosyltransferase (UGT) 1A6
Drug Metab. Dispos., January 1, 2003; 31(1): 133 - 139.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. H. Tran, L. L. von Moltke, K. Venkatakrishnan, B. W. Granda, M. A. Gibbs, R. S. Obach, J. S. Harmatz, and D. J. Greenblatt
Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors
Drug Metab. Dispos., December 1, 2002; 30(12): 1441 - 1445.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. H. Court, S. X. Duan, C. Guillemette, K. Journault, S. Krishnaswamy, L. L. von Moltke, and D. J. Greenblatt
Stereoselective Conjugation of Oxazepam by Human UDP-Glucuronosyltransferases (UGTs): S-Oxazepam Is Glucuronidated by UGT2B15, While R-Oxazepam Is Glucuronidated by UGT2B7 and UGT1A9
Drug Metab. Dispos., November 1, 2002; 30(11): 1257 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Kotegawa, B. E. Laurijssens, L. L. von Moltke, M. M. Cotreau, M. D. Perloff, K. Venkatakrishnan, J. S. Warrington, B. W. Granda, J. S. Harmatz, and D. J. Greenblatt
In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1228 - 1237.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. S. Warrington, L. L. von Moltke, R. I. Shader, and D. J. Greenblatt
In Vitro Biotransformation of Sildenafil (Viagra) in the Male Rat: The Role of CYP2C11
Drug Metab. Dispos., June 1, 2002; 30(6): 655 - 657.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Clinical Pharmacology